

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (OP-26) DARAXONRASIB

PRONUNCIATION da rak" son ras' ib


THERAPEUTIC CLAIM Treatment of patients with advanced solid tumors harboring RAS mutations

CHEMICAL NAMES

Cyclopropanecarboxamide, *N*-[(2*R*,14*S*,18*S*)-1-ethyl-18,19,20,21-tetrahydro-2-[2-[(1*S*)-1-methoxyethyl]-5-(4-methyl-1-piperazinyl)-3-pyridinyl]-25,25-dimethyl-15,22-dioxo-17*H*-5,3-([4,2]-*endo*-thiazolopropano[1,3]-*endo*-pyridazinomethanoxypropano)-1*H*-indol-14-yl]-2-methyl-, (1*S*,2*S*)-

(1*S*,2*S*)-*N*-[(1²*M*,4*S*,6³*S*)-1¹-ethyl-1²-{2-[(1*S*)-1-methoxyethyl]-5-(4-methylpiperazin-1-yl)pyridin-3-yl}-10,10-dimethyl-5,7-dioxo-1¹*H*-8-oxa-1(5,3)-indola-6(1,3)-[1,2]diazinana-2(4,2)-[1,3]thiazolacycloundecaphan-4-yl]-2-methylcyclopropane-1-carboxamide

STRUCTURAL FORMULA



MOLECULAR FORMULA C₄₄H₅₈N₈O₅S

MOLECULAR WEIGHT 811.06

TRADEMARK None as yet

SPONSOR Revolution Medicines, Inc.

CODE DESIGNATIONS RMC-6236

CAS REGISTRY NUMBER 2765081-21-6

UNII B6T47Y2UAP

WHO NUMBER 13270

GBK